MedTrace Logo

Phase 1/2 Study of KRRO-121 in Healthy Volunteers and Patients With UCD

NCT07773246 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-08-20

No results posted yet for this study

Summary

Phase 1/2 Study of KRRO-121 is a randomized, placebo-controlled study in Healthy Volunteers (Phase 1 SAD and MAD) and Study Participants with Urea Cycle Disorders (Phase 2). The primary objective of the study is to evaluate the safety of KRRO-121.

Conditions

  • Urea Cycle Disorders, Inborn
  • Urea Cycle Disorders
  • Ornithine Transcarbamylase (OTC) Deficiency
  • Arginase 1 Deficiency
  • NAGS Deficiency
  • Carbamylphosphate Synthetase I
  • Ornithine Transporter Mitochondrial 1
  • Argininosuccinate Synthase
  • Argininosuccinate Lyase Deficiency
  • N-acetyl Glutamate - Synthetase
  • Citrin Deficiency

Interventions

DRUG

KRRO-121

KRRO-121, subcutaneous injection

DRUG

Placebo

Placebo, subcutaneous injection

Sponsors & Collaborators

  • Korro Bio, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-08-31
Completion
2027-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07773246 on ClinicalTrials.gov